France is transit point for fake Viagra
Over 360,000 counterfeit drug pills have been seized by customs officers at Charles de Gaulle Airport (Roissy), France, over the past three weeks, according to a govern-ment statement. The drugs, imitations of global drug major Pfizer's Viagra (sildenafil citrate), were seized at Paris' main international airport and are believed to have origi-nated in India.
Pfizer: "French market not the target"
Sylvia Cukier, Pfizer France's director of media relations, told the Marketletter that "this is not the first seizure of this kind. In 2004, notably a major haul of fake Viagra in transit for west Africa was seized at Roissy airport."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze